Notice: This company has been marked as potentially delisted and may not be actively trading. ERYTECH Pharma (ERYP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends ERYP vs. SGMO, PRME, FDMT, ALEC, DNA, VALN, ENGN, JSPR, KOD, and ITOSShould you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Sangamo Therapeutics (SGMO), Prime Medicine (PRME), 4D Molecular Therapeutics (FDMT), Alector (ALEC), Ginkgo Bioworks (DNA), Valneva (VALN), enGene (ENGN), Jasper Therapeutics (JSPR), Kodiak Sciences (KOD), and iTeos Therapeutics (ITOS). These companies are all part of the "biological products, except diagnostic" industry. ERYTECH Pharma vs. Sangamo Therapeutics Prime Medicine 4D Molecular Therapeutics Alector Ginkgo Bioworks Valneva enGene Jasper Therapeutics Kodiak Sciences iTeos Therapeutics Sangamo Therapeutics (NASDAQ:SGMO) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment. Which has higher valuation and earnings, SGMO or ERYP? ERYTECH Pharma has lower revenue, but higher earnings than Sangamo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSangamo Therapeutics$176.23M2.33-$257.83M-$0.75-2.63ERYTECH Pharma$32.66M3.24-$240KN/AN/A Do insiders & institutionals believe in SGMO or ERYP? 56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 1.1% of ERYTECH Pharma shares are held by institutional investors. 2.8% of Sangamo Therapeutics shares are held by insiders. Comparatively, 1.9% of ERYTECH Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is SGMO or ERYP more profitable? ERYTECH Pharma has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -257.87%. ERYTECH Pharma's return on equity of 0.00% beat Sangamo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics-257.87% -264.16% -107.24% ERYTECH Pharma N/A N/A N/A Does the media favor SGMO or ERYP? In the previous week, Sangamo Therapeutics had 12 more articles in the media than ERYTECH Pharma. MarketBeat recorded 12 mentions for Sangamo Therapeutics and 0 mentions for ERYTECH Pharma. Sangamo Therapeutics' average media sentiment score of 0.33 beat ERYTECH Pharma's score of 0.00 indicating that Sangamo Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Sangamo Therapeutics Neutral ERYTECH Pharma Neutral Does the MarketBeat Community favor SGMO or ERYP? Sangamo Therapeutics received 284 more outperform votes than ERYTECH Pharma when rated by MarketBeat users. Likewise, 62.55% of users gave Sangamo Therapeutics an outperform vote while only 57.45% of users gave ERYTECH Pharma an outperform vote. CompanyUnderperformOutperformSangamo TherapeuticsOutperform Votes44662.55% Underperform Votes26737.45% ERYTECH PharmaOutperform Votes16257.45% Underperform Votes12042.55% Which has more risk and volatility, SGMO or ERYP? Sangamo Therapeutics has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.69, meaning that its stock price is 169% more volatile than the S&P 500. Do analysts recommend SGMO or ERYP? Sangamo Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 255.47%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Sangamo Therapeutics is more favorable than ERYTECH Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67ERYTECH Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummarySangamo Therapeutics beats ERYTECH Pharma on 10 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get ERYTECH Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERYP vs. The Competition Export to ExcelMetricERYTECH PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.77M$2.99B$5.14B$8.84BDividend YieldN/A1.91%5.05%4.07%P/E RatioN/A36.31125.0517.04Price / Sales3.24283.851,232.2287.12Price / CashN/A169.3839.9936.27Price / Book3.884.416.956.36Net Income-$240,000.00-$41.63M$119.41M$226.00M ERYTECH Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERYPERYTECH PharmaN/A$3.10flatN/AN/A$105.77M$32.66M0.0049SGMOSangamo Therapeutics2.188 of 5 stars$1.97+1.0%$7.00+255.5%+369.9%$410.87M$176.23M-2.63480Analyst RevisionPRMEPrime Medicine3.0894 of 5 stars$2.99flat$13.25+343.1%-57.0%$392.17MN/A-1.47234Analyst RevisionFDMT4D Molecular Therapeutics3.0372 of 5 stars$7.99-5.0%$42.13+427.2%-32.1%$369.38M$20.72M-2.80201Analyst ForecastAnalyst RevisionNews CoverageALECAlector4.3881 of 5 stars$3.76+3.3%$20.67+449.6%-26.1%$368.22M$97.06M-2.14270Positive NewsDNAGinkgo Bioworks1.1513 of 5 stars$6.59+3.5%$4.58-30.5%N/A$365.99M$251.46M-0.501,218Short Interest ↓VALNValneva2.2985 of 5 stars$4.42-5.4%$18.50+318.6%-62.1%$359.13M$165.52M-34.00700Gap DownENGNenGene3.079 of 5 stars$7.67+2.3%$31.43+309.8%-11.3%$339.17MN/A0.0031Analyst ForecastJSPRJasper Therapeutics2.6678 of 5 stars$21.84+4.1%$74.86+242.8%+227.3%$327.60MN/A-4.6120KODKodiak Sciences2.9878 of 5 stars$5.90+1.9%$3.50-40.7%+138.3%$310.46MN/A-1.6290ITOSiTeos Therapeutics3.5163 of 5 stars$8.16+3.9%$31.50+286.0%-23.0%$298.09M$12.60M-2.5990 Related Companies and Tools Related Companies SGMO Alternatives PRME Alternatives FDMT Alternatives ALEC Alternatives DNA Alternatives VALN Alternatives ENGN Alternatives JSPR Alternatives KOD Alternatives ITOS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ERYP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share ERYTECH Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
